Pre-surgical neoadjuvant treatment shows promise in trial for patients with operable NSCLC

For patients with operable non-small cell lung cancer (NSCLC), pre-surgical "neoadjuvant" treatment with an immune checkpoint inhibitor was well tolerated and, in many cases, caused significant tumor cell death in a large, multicenter clinical trial involving investigators at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and nine other research centers. Interim results of the trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.

Participants in the trial had surgically removable NSCLC ranging from stage IB to IIIB. Patients were treated with two cycles of atezolizumab, which blocks the PD-L1 immune checkpoint protein on some cancer cells, then had surgery to remove the lung cancer tissue.

The results to be reported today involve the first 101 participants in the trial, 90 of whom had surgery following treatment with atezolizumab. Excluding eight patients whose cancers had driver mutations, 15 participants (representing 18% of the total) had a major pathologic response to the treatment, defined as 10% or fewer viable cancer cells detected in the surgically removed tumor tissue. Four patients had a pathological complete response, an absence of residual cancer following the neoadjuvant therapy. Seventy-two of the participants had stable disease, and four had their disease progress.

Treatment related adverse events rated as Grade 3 or 4 - considered severe or urgent - occurred in six of the 90 participants.

Immune checkpoint therapy is included as a standard of care for patients with advanced (metastatic) lung cancer, and this study suggests that it may also have benefit in early stage, operable lung cancer."

Study's lead author, David Kwiatkowski, MD, PhD, senior physician at Dana-Farber/Brigham and Women's Cancer Center

Researchers will present Abstract #8503 at the Lung Cancer--Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers session on Saturday, June 1 at 2:15 p.m. CT in Hall D2 of the McCormick Place.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Study sheds light on how ‘junk DNA’ affects inherited cancer risk